Charles River Laboratories International, Inc. provides products and services used in drug discovery, early-stage development, safety assessment, and the manufacture of new therapies. Company news commonly covers results from its Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions activities, along with updates on research models, nonclinical toxicology, microbial and biologics testing, and client demand trends.
Recurring developments also include digital pathology initiatives, AI-enabled workflow tools, rat in vitro fertility services, virtual control groups, and the Alternative Methods Advancement Project™, which relate to efficiency and reduced animal use where scientifically appropriate. Financial releases, investor presentations, governance updates, and portfolio changes are also recurring disclosure themes for CRL.
Charles River Laboratories International (CRL) has announced a collaboration with Magellan Stem Cells to support development of its stem cell-based therapies.
Charles River will provide viral safety testing using next-generation sequencing, a method for analyzing genetic material, under current Good Manufacturing Practice standards. The work supports Magellan’s osteoarthritis candidate Zelestrocel and future programs. Magellan recently concluded Phase I/II trials and is preparing to launch a pivotal Phase III program. The collaboration aims to support development toward potential commercialization, not an approved commercial launch.
Charles River Laboratories (NYSE: CRL) will release third-quarter 2026 financial results on November 4, before the market opens.
A conference call will follow at 9:00 a.m. ET that day. Investors can listen to a live webcast through ir.criver.com, where a replay will also be available.
Charles River Laboratories International (CRL) and Autolomous launched Apollo Orchestrate, a capability that connects and digitizes laboratory execution within Charles River’s Apollo platform.
Built on Autolomous’s autoloMATE laboratory execution system, the deployment covers Biologics Testing Solutions sites across North America and Europe. Initial deployment supports quality-control testing under Good Manufacturing Practice requirements. The capability connects Apollo and LabWare LIMS laboratory systems, moving paper records into a digital workflow from sample submission through execution and review. Charles River plans expansion across Biologics Testing Solutions sites following the initial go-live.
Charles River Laboratories International (CRL) reaffirmed 2026 guidance and set financial targets through 2030 at its September 24 investor day.
The company expects 2026 organic revenue growth and non-GAAP earnings per share at the upper ends of their prior ranges of 0%–1% and $11.15–$11.45, respectively. Its 2026 non-GAAP operating margin guidance remains 21.0%–21.3%. For 2027–2030, it targets 5%–7% annual organic revenue growth and low-double-digit annual non-GAAP EPS growth, with an approximately 24% non-GAAP operating margin in 2030. The targets exclude future acquisitions and divestitures and are not financial guidance.
Under its Pathway to Purpose plan, Charles River expects its Create the Future program to generate over $300 million in cumulative savings from 2027 through 2030. It also expects bioanalysis revenue to grow organically at a high-single-digit annual rate to approximately $450 million in 2030.
Charles River (CRL) launched rapid cell banking programs that target a 40% reduction in cell bank production timelines compared with the industry standard of about 20 weeks. The offering combines accelerated cell bank and release testing with in vitro characterization using Next-Generation Sequencing (NGS) to help biopharmaceutical and advanced therapy developers reach development milestones faster.
The platform uses rapid microbiological methods, including Celsis ATP-bioluminescence, and real-time PCR for mycoplasma to replace traditional compendial tests with automated, objective results. NGS services are delivered via the iDTECT platform under CGMP-compliant conditions aligned with FDA, EMA and ICH Q5A/Q5B guidance, supporting regulatory submissions and product quality assurance. Capabilities are further strengthened by the acquisition of Pathoquest and are positioned under the company’s Alternative Methods Advancement Project (AMAP), which aims to reduce reliance on animal testing.
Charles River Laboratories (CRL) will present at two investor conferences in September 2026. Management will speak at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, at 10:00 a.m. ET, and at the Baird 2026 Global Healthcare Conference on Tuesday, September 15, at 9:40 a.m. ET. Each presentation will cover the company’s strategic focus, business developments, and recent trends, and will be accessible via live webcast and replay for at least two weeks through links on the Investor Relations section of the Charles River website at ir.criver.com.
Charles River Laboratories (CRL) has brought its Endosafe® Cartridge Technology Automated Manufacturing Suite to full operational capacity in Q3 2026, modernizing endotoxin testing cartridge production with expanded in‑process inspection, digital traceability and higher output.
Since becoming fully operational in July 2026, the automated suite has delivered a 2% reduction in scrap rates, a 13% reduction in invalid cartridge rates, and a 14% increase in production capacity across Trillium™ and LAL cartridges. Labor productivity and manufacturing efficiency have improved by 87%, allowing higher throughput with fewer production resources while reducing the risk of human error. The system inspects every cartridge across multiple quality parameters, uses automated flat‑tray packaging to enhance raw material consistency, and assigns a unique ID to each cartridge to support full lifecycle traceability and continuous improvement.
Charles River Laboratories (NYSE: CRL) and Medigen Vaccine Biologics Corp (MVC) have entered a collaboration focused on characterizing and validating the virus seed bank for MVC’s next-generation multivalent enterovirus vaccine. Charles River will apply its advanced analytical platforms, including cGMP-compliant Next-Generation Sequencing (NGS), to support key Chemistry, Manufacturing, and Controls (CMC) activities and IND-enabling non-clinical studies.
The partnership combines Charles River’s global biologics testing, virology, toxicology, and non-clinical development capabilities with MVC’s proven vaccine R&D and manufacturing expertise, including its ENVACGEN Enterovirus 71 vaccine approved in Taiwan and Vietnam. The companies aim to generate robust data for IND applications, enhance global regulatory readiness, and potentially extend their collaboration to additional vaccine programs targeting infectious diseases and unmet medical needs. Charles River’s acquisition of Pathoquest further strengthens its NGS-based testing offering for biopharmaceutical clients.
Charles River Laboratories (NYSE: CRL) reported second-quarter 2026 revenue of $1.00 billion, down 2.7% year over year, with 0.1% organic growth. GAAP loss per share was $(0.03), driven largely by a $63.7 million loss on CDMO and Cell Solutions divestitures, while non-GAAP EPS was $3.02, down 3.2%.
GAAP operating margin rose to 11.9% from 9.7%, and non-GAAP operating margin was 20.5%, up 420 bps sequentially but below 22.1% a year ago. The DSA and Manufacturing segments delivered modest organic growth, offset by RMS declines. Manufacturing margins expanded significantly following the CDMO divestiture.
The company raised 2026 guidance for revenue (reported decline now 3.5%–2.5% vs. 5.5%–4.0% prior) and non-GAAP EPS to $11.15–$11.45, while cutting GAAP EPS guidance to $3.05–$3.35. Charles River repurchased $100 million of stock in Q2 (total $300 million year-to-date) and completed portfolio streamlining divestitures. It also joined Eli Lilly’s TuneLab AI/ML platform, began an NGS collaboration with Arovella Therapeutics, and introduced an AI-enabled digital pathology workflow.
Charles River Laboratories (NYSE: CRL) will release its second-quarter 2026 financial results on Wednesday, August 5, before the market opens. On the same day at 9:00 a.m. ET, the company will host a conference call, with a live webcast and replay available via the Investor Relations section of its website at ir.criver.com.